Table 5 Extracorporeal liver support therapy in primary vs. secondary (cardiac surgery) liver failure
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2007–2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Overall ELS therapies, n | 314 | 311 | 390 | 377 | 287 | 270 | 255 | 294 | 388 | 2886 |
Mortality (%) | 57.32 | 55.63 | 46.41 | 46.42 | 52.61 | 55.18 | 61.18 | 50.00 | 44.84 | 51,49 |
Primary ALS, n (% of all ELS) | 152 (48.41) | 156 (50.16) | 182 (46.67) | 189 (50.13) | 132 (45.99) | 97 (35.93) | 102(40.00) | 92 (31.29) | 131 (33.76) | 1233 (42.72) |
Mortality (%) | 48,03 | 42,95 | 32,42 | 30,16 | 36,36 | 44,33 | 55,88 | 42,39 | 44,27 | 40,63 |
Secondary ALS, n (% of all ELS) | 115 (36,62) | 129 (41,48) | 126 (32,31) | 139 (36,87) | 121 (42,16) | 157 (58,15) | 140 (54,90) | 190 (64,63) | 196 (50,52) | 1313 (45,50) |
Mortality (%) | 80,00 | 75,19 | 69,84 | 62,59 | 77,69 | 64,97 | 69,29 | 54,74 | 69,90 | 68,39 |